metformin and Bacteriuria
metformin has been researched along with Bacteriuria in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Bacteriuria: The presence of bacteria in the urine which is normally bacteria-free. These bacteria are from the URINARY TRACT and are not contaminants of the surrounding tissues. Bacteriuria can be symptomatic or asymptomatic. Significant bacteriuria is an indicator of urinary tract infection.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"To examine the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor that lowers blood glucose by increasing urinary glucose excretion (UGE), on asymptomatic bacteriuria and urinary tract infections (UTIs)." | 9.16 | Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. ( Capuano, G; Nicolle, LE; Usiskin, K; Ways, K, 2012) |
"To examine the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor that lowers blood glucose by increasing urinary glucose excretion (UGE), on asymptomatic bacteriuria and urinary tract infections (UTIs)." | 5.16 | Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. ( Capuano, G; Nicolle, LE; Usiskin, K; Ways, K, 2012) |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Nicolle, LE | 1 |
Capuano, G | 1 |
Ways, K | 1 |
Usiskin, K | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 [NCT00642278] | Phase 2 | 451 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Absolute Change in Body Weight From Baseline to Week 12
The table below shows the mean absolute change in body weight from Baseline to Week 12 for each treatment group. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
Intervention | kg (Mean) |
---|---|
Placebo | -0.78 |
Canagliflozin 50 mg Daily | -1.96 |
Canagliflozin 100 mg Daily | -2.25 |
Canagliflozin 200 mg Daily | -2.32 |
Canagliflozin 300 mg Daily | -2.88 |
Canagliflozin 300 mg Twice Daily | -2.87 |
Sitagliptin 100 mg Daily | -0.43 |
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12
The table below shows the mean change in FPG from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
Intervention | mmol/L (Mean) |
---|---|
Placebo | 0.2 |
Canagliflozin 50 mg Daily | -0.9 |
Canagliflozin 100 mg Daily | -1.4 |
Canagliflozin 200 mg Daily | -1.5 |
Canagliflozin 300 mg Daily | -1.4 |
Canagliflozin 300 mg Twice Daily | -1.3 |
Sitagliptin 100 mg Daily | -0.7 |
Change in HbA1c From Baseline to Week 12
The table below shows the mean change in HbA1c from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
Intervention | Percent (Mean) |
---|---|
Placebo | -0.22 |
Canagliflozin 50 mg Daily | -0.79 |
Canagliflozin 100 mg Daily | -0.76 |
Canagliflozin 200 mg Daily | -0.70 |
Canagliflozin 300 mg Daily | -0.92 |
Canagliflozin 300 mg Twice Daily | -0.95 |
Sitagliptin 100 mg Daily | -0.74 |
Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12
The table below shows the mean change in overnight urine glucose/creatinine ratio from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
Intervention | mg/mg (Mean) |
---|---|
Placebo | 1.9 |
Canagliflozin 50 mg Daily | 35.4 |
Canagliflozin 100 mg Daily | 51.5 |
Canagliflozin 200 mg Daily | 50.5 |
Canagliflozin 300 mg Daily | 49.4 |
Canagliflozin 300 mg Twice Daily | 61.6 |
Sitagliptin 100 mg Daily | -1.9 |
Percent Change in Body Weight From Baseline to Week 12
The table below shows the mean percent change in body weight from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
Intervention | Percent change (Mean) |
---|---|
Placebo | -1.1 |
Canagliflozin 50 mg Daily | -2.3 |
Canagliflozin 100 mg Daily | -2.6 |
Canagliflozin 200 mg Daily | -2.7 |
Canagliflozin 300 mg Daily | -3.4 |
Canagliflozin 300 mg Twice Daily | -3.4 |
Sitagliptin 100 mg Daily | -0.6 |
Percentage of Patients With Symptoms of Hypoglycemia
The table below shows the percentage of patients who experienced symptomatic hypoglycemic events between Baseline and Week 12. (NCT00642278)
Timeframe: Up to Week 12
Intervention | Percentage of patients (Number) |
---|---|
Placebo | 2 |
Canagliflozin 50 mg Daily | 0 |
Canagliflozin 100 mg Daily | 2 |
Canagliflozin 200 mg Daily | 6 |
Canagliflozin 300 mg Daily | 0 |
Canagliflozin 300 mg Twice Daily | 3 |
Sitagliptin 100 mg Daily | 5 |
Trials
1 trial available for metformin and Bacteriuria
Article | Year |
---|---|
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2012 |